VYNDAQEL: payments to doctors
Payments that named VYNDAQEL as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $11.8M
- Providers
- 36,054
- Transactions
- 159,952
- Average per transaction
- $74
The per-transaction average — $74 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 36,054 providers the average total is $329, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Pfizer | $11,770,445 | 99.3% |
| PBG Puerto RICO LLC | $69,252 | 0.6% |
| Pfizer Pharmaceuticals LLC | $5,550 | 0.0% |
| Whitehall International Inc | $2,750 | 0.0% |
| Pfizer Pharmaceuticals Korea Limited | $22 | 0.0% |